Lyra Therapeutics Inc
General ticker "LYRA" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $12.8M
Lyra Therapeutics Inc does not follow the US Stock Market performance with the rate: -41.4%.
Estimated limits based on current volatility of 4.2%: low 0.16$, high 0.18$
Factors to consider:
- Current price 94.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.97$, 7.11$]
- 2024-12-30 to 2025-12-30 estimated range: [2.70$, 6.51$]
Financial Metrics affecting the LYRA estimates:
- Negative: Non-GAAP EPS, $ of -1.26 <= 0.10
- Negative: Operating profit margin, % of -97.73 <= 1.03
- Negative: Operating cash flow per share per price, % of -23.87 <= 2.35
- Negative: negative Net income
Short-term LYRA quotes
Long-term LYRA plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.28MM | $1.36MM | $1.56MM |
| Operating Expenses | $43.90MM | $57.67MM | $68.68MM |
| Operating Income | $-43.62MM | $-56.31MM | $-67.12MM |
| Non-Operating Income | $0.10MM | $1.04MM | $4.50MM |
| R&D Expense | $29.69MM | $38.80MM | $48.03MM |
| Income(Loss) | $-43.51MM | $-55.27MM | $-62.62MM |
| Taxes | $0.00MM | $0.01MM | $0.06MM |
| Profit(Loss) | $-43.51MM | $-55.28MM | $-62.68MM |
| Stockholders Equity | $34.32MM | $80.75MM | $89.42MM |
| Assets | $54.87MM | $109.97MM | $142.60MM |
| Operating Cash Flow | $-25.82MM | $-43.38MM | $-63.30MM |
| Capital expenditure | $3.38MM | $0.16MM | $1.05MM |
| Investing Cash Flow | $-3.38MM | $-65.01MM | $-12.58MM |
| Financing Cash Flow | $0.36MM | $96.26MM | $65.69MM |
| Earnings Per Share* | $-3.27 | $-1.83 | $-1.26 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.